Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METi-101 in Refractory Metastatic Colorectal Cancer (Phase 1b/2a)
KCT0008491Phase 2Recruiting
- Sponsor
- MetiMedi Pharmaceuticals
- Start
- Jan 2023
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of METI-101 in colorectal cancer (CRC), sponsored by MetiMedi Pharmaceuticals. Started Jan 2023; status: recruiting.
02
Drugs
METI-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0008491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008491.